Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study

Xiaomei Xue, Xuan Yuan, Lin Han, Xinde Li, Tony R. Merriman, Lingling Cui, Zhen Liu, Wenyan Sun, Can Wang, Fei Yan, Yuwei He, Aichang Ji, Jie Lü, Changgui LiFrontiers in Medicine 2022 · DOI

TL;DR

This study demonstrates that classifying gout patients based on their urate excretion patterns (renal underexcretion vs. unclassified) significantly improves the effectiveness of low-dose benzbromarone treatment in achieving target serum urate levels. This supports a personalized, etiologically-driven approach to gout management.

What Problem Does This Paper Address?

Gout, a metabolic disease caused by elevated serum urate (SU) levels, leads to painful joint inflammation and can contribute to serious comorbidities like kidney disease, diabetes, and cardiovascular issues. The primary goal of gout treatment is to lower SU levels below a critical threshold (typically < 360 µmol/L) to prevent gout attacks and dissolve existing urate crystals. However, achieving this target remains a significant challenge worldwide, with many patients failing to reach their therapeutic goals.

Current clinical practice often lacks a nuanced approach to hyperuricemia management. While hyperuricemia can arise from different underlying causes (e.g., overproduction or underexcretion of urate), this classification is not widely applied in routine gout management due to a perceived lack of strong clinical evidence. This study aims to bridge this gap by investigating whether a treatment strategy informed by hyperuricemia classification, specifically focusing on renal urate underexcretion, can improve the efficacy of a common urate-lowering drug, benzbromarone, in Chinese gout patients.

Methods

This was a single-center, prospective, controlled clinical study involving 240 Chinese male patients diagnosed with gout. The core of the study involved classifying patients into two groups:

  • Renal Underexcretion Type: Defined by specific criteria for fractional excretion of urate (FEUA < 5.5%) and 24-hour urinary urate excretion (UUE ≤ 600 mg/day/1.73 m²).
  • Unclassified Type: Patients who did not meet the criteria for the underexcretion type.

All participants underwent a 2-week washout period to ensure a clean baseline. They then received low-dose benzbromarone (25 mg daily) and sodium bicarbonate (1 g three times daily) for 12 weeks, with recommendations for increased fluid intake.

The primary endpoint was the proportion of patients achieving the target SU level (< 360 µmol/L) at 12 weeks. Secondary endpoints included the frequency of acute gout attacks, and various physical and chemical indicators (blood and urine parameters, liver and kidney function). Statistical analysis involved mixed models for longitudinal data and stepwise linear regression to identify predictors of SU levels.

Datasets

The study utilized data collected from 240 Chinese male patients with gout enrolled between May 2019 and July 2020. This constitutes the primary dataset for the study. No external or publicly available datasets were used for training or evaluation.

Key Insights and Ideas

  • Personalized Treatment Pays Off: The most significant insight is that tailoring urate-lowering therapy based on the underlying cause of hyperuricemia (specifically, identifying renal urate underexcretion) leads to demonstrably better outcomes. This challenges the "one-size-fits-all" approach and advocates for a more precise, etiologically driven treatment strategy.
  • Benzbromarone's Efficacy in Underexcretors: The study strongly suggests that benzbromarone, a urate-lowering drug, is particularly effective in patients with renal urate underexcretion. This highlights the importance of drug selection based on patient phenotype.
  • Beyond SU Levels: The study also observed potential benefits in metabolic markers, with the underexcretion group showing lower blood glucose and cholesterol levels. This suggests that effectively managing hyperuricemia through classification might have broader positive impacts on metabolic health.
  • Clinical Utility of Classification: The findings provide robust evidence to support the routine use of hyperuricemia classification in clinical practice for gout management, potentially leading to improved patient outcomes and better adherence to treatment goals.

Key Results

  • Target SU Achievement: At 12 weeks, 60.5% of patients in the renal underexcretion group achieved the target SU level (< 360 µmol/L), compared to only 39.0% in the unclassified type group (P = 0.002). This difference was statistically significant and emerged as early as the 4-week mark.
  • Metabolic Markers: The underexcretion group exhibited significantly lower levels of fasting glucose and cholesterol at various time points during the study compared to the unclassified group.
  • Gout Flares and Renal Function: No significant differences were observed in the frequency of acute gout attacks or changes in estimated glomerular filtration rate (eGFR) and serum creatinine between the two groups.
  • Predictors of SU Levels: In the overall cohort, urate excretion determination, baseline SU, and BMI were significant predictors of final SU levels. In the unclassified group, BMI was the key predictor, while in the underexcretion group, both BMI and eGFR were important.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-Center Study: The findings are from a single center, which may limit generalizability to other populations and healthcare settings.
  • Male-Only Cohort: The study exclusively included male patients, so the results may not directly apply to female gout patients.
  • Limited Drug Comparison: The study focused solely on benzbromarone and did not include comparisons with other urate-lowering drugs like allopurinol or febuxostat.
  • Absence of Allopurinol/Febuxostat Comparison: The study did not compare benzbromarone's efficacy against other common urate-lowering therapies.

Future work could involve multi-center trials to confirm these findings, studies including female patients, and comparative analyses of different urate-lowering drugs based on hyperuricemia classification. The authors strongly recommend that patients with gout be tested for clinical classification when selecting urate-lowering drugs, and suggest low-dose benzbromarone as a first-line option for urate underexcretors without renal insufficiency or contraindications.

Summary updated

Abstract

The increased achievement of target serum urate in the underexcretion group supports the use of a clinical hyperuricemia typing treatment strategy for gout.
BibTeX
@inproceedings{xue2022effect,
  author = {Xiaomei Xue and Xuan Yuan and Lin Han and Xinde Li and Tony R. Merriman and Lingling Cui and Zhen Liu and Wenyan Sun and Can Wang and Fei Yan and Yuwei He and Aichang Ji and Jie Lü and Changgui Li},
  title = {{Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2021.806710},
}
Figure